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Abstract
Background: Studies of the host response to infection often require quantitative measurement of the antiviral
type I interferons (IFN-a/b) in biological samples. The amount of IFN is either determined via its ability to suppress
a sensitive indicator virus, by an IFN-responding reporter cell line, or by ELISA. These assays however are either
time-consuming and lack convenient readouts, or they are rather insensitive and restricted to IFN from a particular
host species.
Results: An IFN-sensitive, Renilla luciferase-expressing Rift Valley fever virus (RVFV-Ren) was generated using reverse
genetics. Human, murine and avian cells were tested for their susceptibility to RVFV-Ren after treatment with
species-specific IFNs. RVFV-Ren was able to infect cells of all three species, and IFN-mediated inhibition of viral
reporter activity occurred in a dose-dependent manner. The sensitivity limit was found to be 1 U/ml IFN, and
comparison with a standard curve allowed to determine the activity of an unknown sample.
Conclusions: RVFV-Ren replicates in cells of several species and is highly sensitive to pre-treatment with IFN. These
properties allowed the development of a rapid, sensitive, and species-independent antiviral assay with a
convenient luciferase-based readout.
Background
Type-I interferons (IFN-a/b) are potent cytokines that
can be released from virtually all vertebrate cells follow-
ing viral infection. They comprise a large number of
IFN-a subspecies and a single IFN-b, and their actions
reflect an important part of the innate immune system
[1]. Upon infection, viruses are detected by one or sev-
eral different pattern recognition receptors and produc-
tion of IFN is induced. Newly synthesized IFNs are
secreted in order to bind to their specific receptor
(which is common for IFN-a and IFN-b)i na na u t o -
crine and paracrine manner. Receptor signaling via the
Jak/Stat pathway leads to the up-regulation of a set of
IFN-stimulated genes (ISGs), some of which having anti-
viral activity. As a consequence, neighbouring cells
establish an antiviral state to prevent viral spread in the
organism [2].
A wide variety of assays has been developed to deter-
mine the presence and activity of antiviral IFNs [3]. One
type of assay is based on the upregulation of ISGs, either
directly by measuring enzymatic ISG products [4], or
indirectly by using cells containing a reporter gene
under control of an IFN-responsive promoter. Often,
the promoter of the Mx gene is used [5-8] due to the
sensitivity and the low background expression of this
ISG [9]. Although cell-line based ISG/reporter assays are
rather convenient, a major drawback is their restriction
to a particular host organism since IFNs bind to their
receptor in a species-specific manner. In a similar vein,
commercially available ELISAs are limited to a particular
type of IFN and a single host species.
The historically oldest and still widely used assay to
determine IFN activity are assays of antiviral activity.
Here, IFN-mediated protection of cells is directly ana-
lyzed after infection with a sensitive challenge virus. The
presence of IFNs is reflected by reduced cytopathic
effects or diminished viral growth [10,11]. Some recent
modifications of this assay take advantage of green
fluorescent protein (GFP)-expressing viruses. These
viruses allow to determine the reduction in virus titers
by counting GFP-positive cells, either manually or by
flow cytometry [12-14].
Rift Valley fever virus (RVFV) is a highly pathogenic
member of the family Bunyaviridae.R V F Ve n c o d e sa * Correspondence: friedemann.weber@uniklinik-freiburg.de
Department of Virology, University of Freiburg, D-79008 Freiburg, Germany
Kuri et al. Virology Journal 2010, 7:50
http://www.virologyj.com/content/7/1/50
© 2010 Kuri et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.non-structural gene termed NSs which is mainly
responsible for the pathogenicity of this virus [15,16].
Mutant RVFV lacking the NSs gene are thus highly
sensitive to IFN-induced antiviral proteins such as
MxA and PKR [17-20]. Here, we applied our recently
developed reverse genetics system for RVFV [21] and
replaced the NSs gene with the Renilla luciferase
reporter gene, resulting in an attenuated, IFN-sensitive
virus. We used this virus to establish a bioassay for
quantification of IFN that combines the advantages of
the classical antiviral assay with the convenience of
luciferase reporter assays.
Results and discussion
Establishment of a luciferase-based antiviral IFN assay
Using our reverse genetics system [21], we generated the
recombinant virus RVFV-Ren with the IFN antagonist
NSs replaced by Renilla luciferase (see Materials and
Methods). Luciferase expression by this virus was corre-
lating with viral replication and remained stable over
several passages (data not shown). We then tested the
IFN sensitivity of RVFV-Ren in human A549 cells. Cells
were seeded in 96-well microtiter plates and pre-treated
with serial dilutions of standard IFN for 7 hours to
allow the establishment of an antiviral state. Afterwards,
cells were infected with RVFV-Ren at an MOI of 1 for
16 hours and Renilla luciferase activity was measured in
cell lysates (Fig. 1A). To determine the linear range of
the assay, IFN dilutions from 0.5 U/ml up to 100 U/ml
were tested. A significant reduction of luciferase activity
was observed using IFN concentrations from 1 U/ml on
(Fig. 1B). The highest concentration of IFN in the linear
range was 50 U/ml.
Measurement of IFN in biological samples
We used the RVFV-Ren assay to quantify IFN induction
by two recombinant viruses which had been generated
by our group. Wild-type (wt) La Crosse virus is able to
suppress IFN induction, whereas a mutant virus upregu-
lates the IFN-b gene [22]. Supernatants were taken from
cells infected with these viruses and sterilized with b-
propiolactone to destroy infectiousness. After removal of
the disinfectant, undiluted and serially diluted samples
of supernatants were subjected to the RVFV-Ren assay
in parallel to the serial dilutions of standard IFN (see
Fig. 1B). The IFN dilutions were used to create a stan-
dard curve by regression analysis (Fig. 2A) which, in
turn, served to calculate IFN concentrations of the La
Crosse virus supernatants. For cells infected with wt La
Crosse virus, the activity of the undiluted supernatants
was taken to determine the amount of type I IFN. For
the mutant virus, we had to use the 1:10 dilution as the
basis for the calculations since undiluted supernatants
would have been out of the linear range of the assay. As
expected, only little IFN was present in supernatants of
cells infected with wt La Crosse virus, but substantial
amounts were measured in the supernatant of mutant
virus-infected cells (Fig 2B).
Figure 1 Principle and evaluation of the RVFV-Ren antiviral assay. (A) Schematic outline of the RVFV-Ren antiviral assay. (B) Dose-response
curve in human A549 cells. A549 cells seeded in 96-well plates were treated with increasing doses of Multiferon for 7 hours before infection
with 10,000 plaque forming units of RVFV-Ren. Sixteen hours later, cells were lysed and Renilla luciferase activity in cell lysates was determined.
All measurements were performed in triplicate wells under standard conditions; shown are means ± SD. Both axes are plotted in logarithmic
scale; the dotted vertical line indicates the threshold of sensitivity, based on the mean + 2SD of an untreated control run in triplicate; shaded
area shows the linear range of the assay; RLU, relative light units.
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Since RVFV is able to infect a broad range of vertebrate
hosts, we wanted to know whether the assay which was
established for human IFN could be adapted to measure
IFN from other species. To this aim, we infected L929
mouse cells and chicken embryo fibroblasts (CEFs), and
tested the anti-RVFV-Ren activity of murine and avian
IFN, respectively. As shown in Figure 3, RVFV-Ren was
able to replicate in both cell lines and viral growth was
inhibited in a dose-dependent manner by the species-
compatible IFN. The sensitivity of the assay on L929
(Fig. 3A) as well as on CEFs (Fig. 3B) was comparable
to human cells, with a linear range from 1 to 50 U/ml
and from 1 to 25 U/ml, respectively.
The RVFV-Ren assay measures type I IFNs
Type I IFNs are the main, but not the only, cytokines
produced during an innate immune response. We
wanted to know whether other antiviral molecules, e.g.
IFN-l, could disturb our bioassay. To investigate this,
we employed embryo fibroblasts from knockout mice
lacking the receptor for type I IFNs (IFNAR-/- MEFs).
Supernatants containing antiviral mouse cytokines were
obtained by infecting L929 cells with the RVFV strain
clone 13 [15,16], a virus mutant which in our experience
is one of the strongest inducers of antiviral cytokines.
Clone 13 upregulated an innate immune response
including IFN-b, as expected (Fig. 4A). When we per-
f o r m e dt h eb i o a s s a yo nI F N A R - / -M E F s ,t h ei n d i c a t o r
virus RVFV-Ren was not inhibited by IFN-a,a s
expected, but also not by supernatants (Fig. 4B). This
strongly indicates that it is type I IFNs which are caus-
ing the antiviral effect against RVFV-Ren.
Similar to the conventional virus inhibition or GFP-
virus-based IFN bioassays, it can not be excluded a
priori that material derived frome . g .i n f e c t e dd e n d r i t i c
cells or clinical samples may contain antiviral cytokines
other than type I IFNs which could inhibit RVRV-Ren.
Depending on the species material, IFNAR -/- MEFs,
other mutant cell lines, acid treatment, or IFNAR-neu-
tralizing antisera could be employed to verify that only
type I IFNs are causing RVFV-Ren inhibition. However,
in many cases supernatants from tissue cells are used, a
system in which apparently type I IFNs are the domi-
nant antiviral cytokine.
Conclusions
Here we established a novel antiviral bioassay based on
a recombinant RVFV encoding the gene for Renilla
luciferase in place of the IFN-antagonistic NSs gene
Figure 2 Measurement of IFN in samples by the RVFV-Ren antiviral assay. (A) Generation of the standard curve. All data points from Figure
1B which are above the sensitivity threshold and within the linear range of the assay (from 1-50 U/ml) are plotted. Non-linear regression analysis
was performed to generate a standard curve and to compute the regression equation. Values for the slope (k) and the y-axis interception point
(d) were -0.3988 and 5.159, respectively. The coefficient of regression (R
2) indicates the linearity of detection. (B) Analysis of two samples with
low and high concentration of IFN. Supernatants from human A549 cells infected with wt mutant La Crosse virus were first sterilized with b-
propiolactone (see Methods section) and then analyzed for inhibition of RVFV-Ren. Sterilized supernatant from uninfected cells served as control
(mock). The IFN content of all samples was extrapolated from the standard curve shown in (A). All measurements were performed in triplicate;
columns show means ± SD, with actual values given above each column.
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a dose-dependent manner, which can easily be moni-
tored by the measurement of luciferase activity in lysates
of infected cells. Furthermore, IFN of at least three dif-
ferent species was reliably measured, indicating that
RVFV-Ren not only infects cells of human or murine
origin, as previously known, but also bird cells. The lat-
ter fact indicates that the RVFV-Ren assay could be
used for other, less established species as well, e.g. bats.
Our results show that these properties make this virus a
useful tool for quantitative, species-independent mea-
surement of IFN in biological samples, and that the use
of luciferase and the 96-well plate format greatly facili-
tates readout. RVFV is classified as a BSL3 pathogen,
and RVFV-Ren also needs to be handled under BSL3
conditions. The principle of our assay, however, namely
the use of an IFN-sensitive virus expressing Renilla luci-
ferase might as well be adapted for IFN-sensitive non-
BSL3 viruses with a broad host range such as Vesicular
stomatitis virus or Newcastle disease virus.
Methods
Cells and viruses
BHK-21, Vero E6 (ATCC; CRL-1586), 293T (ATCC;
CRL-11268), human A549 (ATCC; CCL-185) cells, and
murine L929 cells (ATCC; CCL-1) and IFNAR -/- MEFs
(kindly provided from Jovan Pavlovic, University of Zur-
ich, Switzerland) were cultivated in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS; Biochrom AG) and antibiotics. Chicken
embryo fibroblasts (CEF) were prepared from 10-day-old
chicken embryos and maintained in DMEM with 2%
chicken serum (Invitrogen), 8% FCS and antibiotics.
Viruses used in this study were recombinant Rift Valley
fever virus (RVFV) expressing Renilla luciferase (see
below), RVFV Clone 13 [15,16], and recombinant La
Crosse viruses expressing (wt) or lacking expression
(mutant) of the NSs gene [22]. Virus titers were deter-
mined by standard plaque assay on Vero E6 cells.
Interferons
Recombinant pan-species IFN-a (IFN-a B/D BglII) was
purchased from PBL Biomedical Laboratories, and Mul-
tiferon, a mix of natural human IFN-a subtypes, was
from Viragen. Recombinant chicken interferon (chIFN)
Figure 3 Dose-response curves for mouse and chicken IFNs. Murine L929 cells (A) or CEFs (B) seeded in 96-well plates were pre-treated for
seven hours with increasing doses of pan-species IFN-a and chicken IFN (chIFN), respectively. Both assays were then carried out further as
described for Fig. 1B. All measurements were performed in triplicate wells under standard conditions; shown are means ± SD. Both axes are
plotted in logarithmic scale; the dotted vertical line indicates the threshold of sensitivity, based on the mean + 2SD of an untreated control run
in triplicate; shaded area shows the linear range of the assay.
Figure 4 RFVFV-Ren antiviral assay on cells lacking the type I
IFN receptor. Murine L929 cells were infected with Clone 13 at an
MOI of 1, or left uninfected (mock). After 16 h of infection,
supernatants were harvested and sterilized as described for Fig. 2B.
(A) Determination of IFN-b using a commercial ELISA. Mean values
from two measurements are shown. (B) Analysis for inhibition of
RVFV-Ren on IFNAR-/- MEFs. Different doses of recombinant pan-
species IFN-a were used as control. Measurements were performed
in triplicate; columns show means ± SD.
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previously [23,24].
Generation of recombinant RVFV expressing Renilla
luciferase
We used our plasmid-based rescue system for genera-
tion of recombinant RVFV[21]. Expression of Renilla
luciferase by RVFV-Ren was achieved by replacing the
non-structural NSs gene on the genomic S segment
with the Renilla gene. The corresponding S segment
rescue plasmid pHH21-RVFV-vN_Ren was generated by
inserting the Renilla luciferase open reading frame,
amplified from plasmid pRL-SV40 (Promega), into the
cloning site of pHH21-RVFV-vN_TCS [21]. RVFV-Ren
was rescued by transfecting cocultures of 293T and
BHK-21 cells in six-well plates with 0.5 μgo fh e l p e r
plasmids (pI.18-RVFV-L and pI.18-RVFV-N), together
with 1 μg each of pHH21-RVFV-vL, pHH21-RVFV-vM,
and pHH21-RVFV-vN_Ren using Nanofectin transfec-
tion reagent (PAA Laboratories). Supernatants contain-
ing recombinant viruses were collected 5 days post
transfection and used to grow virus stock on Vero E6
cells. All RVFV rescues were performed under biosafety
level (BSL) 3 conditions.
Antiviral bioassay
Prior to measurement of IFN-containing samples,
remaining virus was inactivated using b-propiolactone
(Acros Organics) [11,25]. Briefly, supernatants were first
incubated in the presence of 0.05% b-propiolactone in
plastic dishes overnight at 4°C, and then at 37°C for 2
hours for hydrolysis of b-propiolactone.
Approximately 10,000 cells were seeded into each well
of a 96-well microtiter plate and incubated overnight in
a humified incubator at 5% CO2 and 37°C. Cells were
then treated either with different dilutions of standard
IFN or serial ten-fold dilutions of IFN-containing sam-
ples in 100 μl of growth medium for 7 hours. Subse-
quently, cell culture medium was removed and 10,000
plaque forming units of RVFV-Ren in 100 μl of infection
medium (DMEM with 2% FCS and 20 mM HEPES, pH
7.3) were added per well. After 16 hours of further incu-
bation, supernatants were removed and cells lysed in 50
μlo f1×Renilla lysis buffer (Promega). Luciferase activ-
ity in 10 μl of cell lysate was measured using the Renilla
luciferase assay system (Promega), according to the
manufacturer’s instructions.
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